Corradini Elena, Ferrara Francesca, Pietrangelo Antonello
Center for Hemochromatosis and Hereditary Liver Diseases, Department of Internal Medicine, University of Modena and Reggio Emilia, Italy.
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:245-8.
Iron is an important bio-catalyst of oxidation-reduction reactions in the cell and is essential for life. Paradoxically, it may also be lethal when the fraction of redox-active metal ions exceeds that sequestered in specialized proteins or cellular compartments, and uncontrolled production of free radical species may arise. The liver is the main body site for iron stores and central in the regulation of iron homeostasis. Important iron-proteins, such as hepcidin, the iron regulatory hormone, are specifically produced by the liver. Pathogenic mutations in hepatic iron transporters and regulators lead to hereditary iron overload diseases, including hemochromatosis. Iron toxicity depends on its excessive accumulation and is due to promotion of oxidant stress: free radicals and membrane oxidation by-products cause hepatocellular death by triggering organelle dysfunction, or by activating cells involved in hepatic inflammation and fibrogenesis, such as Kupffer cells and hepatic stellate cells. Xenobiotics and hepatotoxins as well as immunological and host defense mechanisms may cause subtle changes in the pool of redox-active metal ions and in metal compartmentalization that potentially contribute to hepatotoxic, inflammatory and fibrogenic events. The hepatotoxic and profibrogenic potential of metal ions, particularly iron, is dramatic at moderate levels of tissue metal overload in concomitance with other inciting insults, such as alcohol abuse and viral hepatitis. Removal of metal excess from the liver in iron overload diseases is beneficial and prevents progression toward cirrhosis. The development of drugs able to block catalytically active metals, particularly iron, may prove effective in other chronic liver diseases in which inflammatory, degenerative and fibrogenic processes are fueled by redox-active metal ions.
铁是细胞内氧化还原反应的重要生物催化剂,对生命至关重要。矛盾的是,当氧化还原活性金属离子的比例超过隔离在特定蛋白质或细胞区室中的比例时,铁也可能是致命的,并且可能会出现自由基的无节制产生。肝脏是铁储存的主要身体部位,也是铁稳态调节的核心。重要的铁蛋白,如铁调节激素铁调素,是由肝脏特异性产生的。肝脏铁转运蛋白和调节因子的致病突变会导致遗传性铁过载疾病,包括血色素沉着症。铁毒性取决于其过度积累,是由于促进氧化应激:自由基和膜氧化副产物通过触发细胞器功能障碍或激活参与肝脏炎症和纤维化形成的细胞,如库普弗细胞和肝星状细胞,导致肝细胞死亡。外源性物质、肝毒素以及免疫和宿主防御机制可能会导致氧化还原活性金属离子池和金属区室化发生细微变化,这些变化可能会导致肝毒性、炎症和纤维化事件。在伴有其他刺激性损伤,如酒精滥用和病毒性肝炎的情况下,金属离子,尤其是铁的肝毒性和促纤维化潜力在中等程度的组织金属过载时非常显著。在铁过载疾病中,从肝脏中去除多余的金属是有益的,可以防止病情发展为肝硬化。能够阻断催化活性金属,尤其是铁的药物的开发,可能在其他慢性肝病中被证明是有效的,在这些疾病中,炎症、退行性变和纤维化过程是由氧化还原活性金属离子推动的。